— End-stage liver disease patients with scores as low as 11 achieved survival of 13 years or beyond
End-stage liver disease patients at lower risk for death in the short term still reaped the substantial benefits of a living-donor liver transplant (LDLT), a case-control study revealed.
Compared with individuals who remained on the transplant waitlist, those with Model for End-Stage Liver Disease incorporating sodium levels (MELD-Na) scores ranging from 6 to 19 gained an additional 13 to 17 years of life following LDLT, reported John Malamon, PhD, of the University of Colorado in Aurora, and colleagues. Read more in MedPage Today.